BioTek reMEDys to Attend Immunoglobulin National Society Meeting

NEW CASTLE, Del.--(BUSINESS WIRE)-- As part of its commitment to expand upon health literacy and explore best practices in the immunoglobulin therapy space, BioTek reMEDys, a multi-site national integrated infusion therapy provider focused on providing support to people with rare diseases, has sent its team of Immunoglobulin National Society (IgNS) certified pharmacists to this week’s IgNS 2023 annual national conference in Denver for the latest clinical education and practice advancements with patients and colleagues.

The Immunoglobulin National Society is a professional organization dedicated to the advancement of immunoglobulin therapy practice, across clinical indications and areas of practice. This year’s in-person conference, which started today and will run through October 8th, is being headlined by renowned keynote speakers and invited lecturers, thought-provoking sessions, and in-depth educational and networking events.

The mission of IgNS is to:

• Develop and sustain evidence-based Ig Therapy standards of practice
• Provide systematic, multi-disciplinary education
• Support best practices through professional certification
• Promote patient-centric initiatives and outcomes

“We’re proud to be long-time supporters of the Immunoglobulin National Society and are excited to be participating this year by sending our pharmacist colleagues to the annual event,” said BioTek reMEDys’ CEO and founder Chaitanya Gadde. “Immunoglobulin therapy is one of the most complex fields of clinical practice, requiring clinicians to possess highly-specialized expertise and skills. As such, IgNS certification and the programs and events the organization offers are critically important so that we as a healthcare community can provide patients with the knowledge, skills, and overall clinical competence of nurses and pharmacists managing and administering Ig therapy.”

BioTek reMEDys is a multi-site national integrated infusion therapy provider focused on providing support to people with rare diseases. Through supply chain management, innovative technology and trained specialty pharmacists, BioTek reMEDys is able to deliver superior service at a lower cost. The company bridges the gap between managed care, physicians and patients by facilitating the authorization, procurement and administration of specialty medications and infusions. BioTek reMEDys provides high-touch therapies, biologics and pharmaceuticals to support treatment for patients with rare diseases and chronic conditions, ensuring the highest quality of care. For information visit www.biotekrx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231005462787/en/

Media Contact:
Paul Williams
[email protected]
310/569-0023

Source: BioTek reMEDys

You May Also Be Interested In

• Tigo Energy Builds on 80MW of C&I Solar Growth in Czechia with GO Optimized ESS for Residential
• Hims & Hers Health Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Hims & Hers Health, Inc. - HIMS
• HDFC Bank Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against HDFC Bank Limited - HDB